1-(5-氨基-2-甲氧基苯基)乙酮 | 85276-70-6

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 1-(5-氨基-2-甲氧基苯基)乙酮
• 英文名称: 5'-amino-2'-methoxyacetophenone
• 英文别名: 1-(5-amino-2-methoxy-phenyl)-ethanone；1-(5-Amino-2-methoxy-phenyl)-aethanon；1-(5-amino-2-methoxyphenyl)ethanone
• CAS: 85276-70-6
• 化学式: C₉H₁₁NO₂
• 分子量: 165.192
• InChiKey: AIDRUCBIROYFNK-UHFFFAOYSA-N

物化性质

• 熔点：
  91°C
• 沸点：
  125-127 °C(Press: 0.25 Torr)
• 密度：
  1.121±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  52.3
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2922509090

反应信息

• 作为反应物：
  描述：

  1-(5-氨基-2-甲氧基苯基)乙酮 生成 乙酸-(3-乙酰基-4-甲氧基苯胺)
  参考文献：
  名称：

  240.对合成抗疟药化学的贡献。第八部分 芳香甲醇胺

  摘要：

  DOI：

  10.1039/jr9490001133
• 作为产物：
  描述：

  2-氯-5-硝基苯甲酸 在 palladium 10% on activated carbon 氯化亚砜 、 氢气 、 三乙胺 、 magnesium chloride 作用下， 以 甲醇 、 甲苯 为溶剂， 反应 18.0h， 生成 1-(5-氨基-2-甲氧基苯基)乙酮
  参考文献：
  名称：

  WO2006/123145

  摘要：

  公开号：

文献信息

• Studies on benzenesulfonamide derivatives with .ALPHA.- and .BETA.-adrenergic antagonistic and antihypertensive activities.
  作者：TAKASHI FUJIKURA、KUNIHIRO NIIGATA、SHINICHI HASHIMOTO、KAZUO IMAI、TOICHI TAKENAKA

  DOI：10.1248/cpb.30.4092

  日期：——

  New α-and β-adrenergic blockers, benzenesulfonamide derivatives (Ia-z), were prepared from acetylbenzenesulfonamides (II) by two methods. These compounds were tested for α-and β-blocking activities and their structure-activity relationships are discussed. All the target compounds have two asymmetric centers and therefore consist of two diastereomers. 5-[1-Hydroxy-2-[3-(2-methoxyphenyl)-1-methylpropylamino]ethyl]-2-methylbenzenesulfonamide (Ir) and 5-[1-hydroxy-2-[2-2-(2-methoxyphenoxy)-1-methylethylamino] ethyl]-2-methylbenzenesulfonamide (Iu) showed potent α-and β-blocking activities and they were each separated into two diastereomers (Ir-A and Ir-B, and Iu-A and Iu-B). It was found that one isomer had mainly β-blocking activity and the other isomer had mainly α-blocking activity. In addition, several compounds showing relatively strong α-and β-blocking activities were also examined for antihypertensive activity in conscious spontaneously hypertensive rats. Among the compounds tested, Ir and Iu were the most active, and they were more potent than labetalol. Compounds Ir and Iu may be of practical use as potent antihypertensive agents.

  通过两种方法从乙酰苯磺酰胺类化合物（II）制备了新型α和β肾上腺素能阻断剂苯磺酰胺衍生物（Ia-z）。对这些化合物进行了α和β阻断活性测试，并讨论了它们的结构-活性关系。所有目标化合物都有两个不对称中心，因此由两种非对映异构体组成。5-[1-羟基-2-[3-(2-甲氧基苯基)-1-甲基丙氨基]乙基]-2-甲基苯磺酰胺（Ir）和 5-[1-羟基-2-[2-2-(2-甲氧基苯氧基)-1-甲基乙基氨基]乙基]-2-甲基苯磺酰胺（Iu）显示了强效的α和β-阻断活性，并分别被分离成两种非对映异构体（Ir-A 和 Ir-B 以及 Iu-A 和 Iu-B）。结果发现，一种异构体主要具有 β-阻断活性，而另一种异构体主要具有 α-阻断活性。此外，研究人员还对几种具有较强α和β阻断活性的化合物进行了研究，以观察它们在有意识的自发性高血压大鼠体内的降压活性。在测试的化合物中，Ir 和 Iu 的活性最高，它们比拉贝洛尔更强。Ir和Iu化合物作为强效降压药可能具有实用价值。
• Amidine derivatives which are inhibitors of nitric oxide synthase
  申请人：——

  公开号：US20020137750A1

  公开（公告）日：2002-09-26

  There are provided novel compounds of formula (I) 1 wherein R 1 , R 2 , X, Y and Z are as defined in the Specification and optical isomers, racemates and tautomers thereof and pharmaceutically acceptable salts thereof; tocether with processes for their preparation, compositions containing them and their use in therapy. The compounds are inhibitors of the enzyme nitric oxide synthase.

  提供了式(I)1的新化合物，其中R1、R2、X、Y和Z如规范中定义，并其光学异构体、消旋体和互变异构体以及其药学上可接受的盐；以及它们的制备过程、含有它们的组合物以及它们在治疗中的应用。这些化合物是一氧化氮合酶的抑制剂。
• [EN] COMPOSITIONS AND METHODS FOR THE TREATMENT OF INFLAMMATION<br/>[FR] COMPOSITIONS ET MÉTHODES POUR LE TRAITEMENT D'UNE INFLAMMATION
  申请人：CELLIX BIO PRIVATE LTD

  公开号：WO2018115984A1

  公开（公告）日：2018-06-28

  The disclosures herein provide compounds of formula I or its pharmaceutical acceptable salts, as well as polymorphs, enantiomers, stereoisomers, solvates, and hydrates thereof. These compounds may be formulated as pharmaceutical compositions. The pharmaceutical compositions may be formulated for oral administration, intravenous, spray, parenteral, lozenge, solution, syrup, sachet, transdermal administration, or injection. Such compositions may be used to treatment of inflammation or its associated complications.

  本公开提供了化合物I的结构或其药用可接受的盐，以及其多晶型、对映体、立体异构体、溶剂合物和水合物。这些化合物可以制备成药物组合物。药物组合物可以制备成口服、静脉注射、喷雾、注射、含片、溶液、糖浆、小包装、经皮给药或注射的药物。这些组合物可用于治疗炎症或其相关并发症。
• Novel compounds
  申请人：——

  公开号：US20020137736A1

  公开（公告）日：2002-09-26

  There are provided novel compounds of formula (I) 1 wherein R 1 , R 2 , R 3 , X and Z are as defined in the Specification and optical isomers, racemates and tautomers thereof and pharmaceutically acceptable salts thereof; together with processes for their preparation, compositions containing them and their use in therapy. The compounds are inhibitors of the enzyme nitric oxide synthase.

  提供了一种化合物，其化学式为（I）1，其中R1、R2、R3、X和Z的定义如规范中所述，以及其光学异构体、消旋体和互变异构体，以及其药用可接受的盐；以及它们的制备过程、含有它们的组合物和它们在治疗中的用途。这些化合物是一氧化氮合酶的抑制剂。
• 3-benzylaminopiperidines as tachykinin receptor antagonists
  申请人：Merck Sharp & Dohme Ltd.

  公开号：US06096766A1

  公开（公告）日：2000-08-01

  The present invention relates to certain 3-benzylaminopiperidines which are tachykinin receptor antagonists and are useful in the treatment or prevention of pain, inflammation, migraine, emesis and postherpetic neuralgia.

  本发明涉及某些3-苄基氨基哌啶，它们是快速激肽受体拮抗剂，可用于治疗或预防疼痛、炎症、偏头痛、恶心和带状疱疹后神经痛。